More US millions flow into Bavarian Nordic for smallpox work  

Bavarian Nordic gains the second part of a US government award to further develop a third generation smallpox vaccine (MVA-BN)

Danish medical company Bavarian Nordic has been granted the second part of an award by the US government to further develop a new, safe third generation smallpox vaccine (MVA-BN). In financial terms the new award has a potential value of up to USD 23 million, in comparison with the first part which has a total value of USD 20 million over a three year period.


The new award will give Bavarian Nordic the opportunity to implement Phase II clinical studies in healthy individuals as well as Phase I and II studies with individuals who belong to a risk group, such as patients with compromised immune defences. MD of Bavarian Nordic Peter Wulffs says that the company is very satisfied that the US government takes the view that MVA-BN shows potential as an efficient smallpox vaccine. Bavarian Nordic is a world leader in research, development and manufacturing of vaccines and immunotherapy against infectious diseases. The news is reported by financial newspaper Børsen online.


Link > Bavarian Nordic

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×